News | June 30, 2022
Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior
The settlement and dismissal resolves all claims between the parties
The settlement and dismissal resolves all claims between the parties
An estimated 21 million American women experience BV
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
The board has approved the settlement of US $ 248 million towards Direct Purchaser group and Retailer Opt-Out group subject to court approval
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Subscribe To Our Newsletter & Stay Updated
